Healthcare - Biotechnology - NASDAQ - US
$ 26.63
-5.06 %
$ 3.91 B
Market Cap
-12.05
P/E
BALANCE SHEET
666 M
ASSETS
48.6 M
LIABILITIES
618 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Immunovant, Inc.
| Current Assets | 666 M |
| Cash & Short-Term Investments | 635 M |
| Receivables | 5.5 M |
| Other Current Assets | 24.9 M |
| Non-Current Assets | 595 K |
| Long-Term Investments | 0 |
| PP&E | 595 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 48.6 M |
| Accounts Payable | 7.16 M |
| Short-Term Debt | 276 K |
| Other Current Liabilities | 41.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
Balance Sheet
Millions
| Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 | Dec-2018 | Mar-2018 | |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Cash & Cash Equivalents | 635.4 | 376.5 | 493.8 | 400.1 | 100.6 | 0.3 | 0 |
| Short Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 5.5 | 0.9 | 12.9 | 1.1 | 3.0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 24.9 | 26.9 | 6.3 | 7.7 | 5.5 | 0 | 0.1 |
| Total Current Assets | 665.8 | 404.3 | 512.9 | 409.0 | 109.1 | 0.3 | 0.1 |
| PP&E | 0.6 | 1.5 | 2.6 | 3.5 | 65 K | 54 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 0 | 0 | 0 | 0 | 0.2 | 79.9 K | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 666.4 | 405.8 | 515.6 | 412.5 | 109.4 | 0.4 | 0.1 |
| LIABILITIES | |||||||
| Accounts Payable | 7.2 | 1.4 | 18.6 | 2.4 | 1.2 | 206 | 1.1 |
| Short Term Debt | 0.3 | 1.2 | 1.1 | 2.4 | 3.2 | 0.3 | 0 |
| Other Current Liabilities | 41.2 | 40.8 | 24.7 | 14.0 | 10.9 | 80.2 K | 0.5 |
| Total Current Liabilities | 48.6 | 43.3 | 44.5 | 18.8 | 15.3 | 0.4 | 1.6 |
| Long Term Debt | 0 | 47 K | 1.2 | 2.2 | 0 | 0 | 0 |
| Deferred Tax Income | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | (0.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 48.6 | 43.3 | 45.7 | 21.0 | 15.3 | 0.4 | 1.6 |
| EQUITY | |||||||
| Common Stock | 14 K | 13 K | 12 K | 10 K | 5 K | 288 | 0 |
| Retained Earnings | (825.7) | (566.3) | (355.4) | (198.7) | (91.2) | 448 | 0 |
| Other Accumulative Comprehensive Income/Loss | 1.9 | 0.9 | 0.4 | (0.3) | 16 K | 0.3 | (1.5) |
| Total Equity | 617.8 | 362.5 | 469.8 | 391.5 | 94.1 | 24.6 K | (1.5) |
| Total Liabilities and Equity | 666.4 | 405.8 | 515.6 | 412.5 | 109.4 | 0.4 | 0.1 |
| SHARES OUTSTANDING | |||||||
| Common Shares Outstanding | 138.1 | 123.1 | 109.7 | 87.8 | 43.2 | 14.4 | 10.0 |